These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1535804)

  • 21. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained gonadal suppression in fertile women with the LHRH agonist buserelin.
    Hardt W; Schmidt-Gollwitzer M
    Clin Endocrinol (Oxf); 1983 Nov; 19(5):613-7. PubMed ID: 6416718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolactin and pituitary gonadotropin values and responses to acute luteinizing hormone-releasing hormone (LHRH) challenge in patients having long-term treatment with a depot LHRH analogue.
    Mahler C; Verhelst J; Chaban M; Denis L
    Cancer; 1991 Feb; 67(3):557-9. PubMed ID: 1824680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zoladex as primary therapy in advanced prostatic cancer. A French cooperative trial.
    Metz R; Namer M; Adenis L; Audhuy B; Bugat R; Colombel P; Couette JE; Grise P; Khater R; LePorz B
    Am J Clin Oncol; 1988; 11 Suppl 2():S112-4. PubMed ID: 2977263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new extra long acting depot preparation of the LHRH analogue Zoladex. First endocrinological and pharmacokinetic data in patients with advanced prostate cancer.
    Dijkman GA; del Moral PF; Plasman JW; Kums JJ; Delaere KP; Debruyne FM; Hutchinson FJ; Furr BJ
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):933-6. PubMed ID: 2149507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suppression of puberty with long-acting goserelin (Zoladex-LA): effect on gonadotrophin response to GnRH in the first treatment cycle.
    Trueman JA; Tillmann V; Cusick CF; Foster P; Patel L; Hall CM; Price DA; Clayton PE
    Clin Endocrinol (Oxf); 2002 Aug; 57(2):223-30. PubMed ID: 12153601
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential role for medroxyprogesterone acetate as an adjunct to goserelin (Zoladex) in the medical management of uterine fibroids.
    West CP; Lumsden MA; Hillier H; Sweeting V; Baird DT
    Hum Reprod; 1992 Mar; 7(3):328-32. PubMed ID: 1534089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
    Lukkarinen O; Kontturi M
    Scand J Urol Nephrol Suppl; 1988; 110():109-12. PubMed ID: 2973121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Goserelin (Zoladex) in premenopausal advanced breast cancer: duration of response and survival.
    Dixon AR; Robertson JF; Jackson L; Nicholson RI; Walker KJ; Blamey RW
    Br J Cancer; 1990 Nov; 62(5):868-70. PubMed ID: 2147110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors.
    Bakker GH; Setyono-Han B; Portengen H; De Jong FH; Foekens JA; Klijn JG
    Endocrinology; 1989 Sep; 125(3):1593-8. PubMed ID: 2527151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of prostatic cancer by monthly injections of an LHRH-analogue depot.
    Hjertberg H; Varenhorst E; Svensson M; Kågedal B; Nordenskjöld B
    Acta Oncol; 1988; 27(4):361-4. PubMed ID: 2974290
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
    Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
    Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630.
    Plowman PN; Nicholson RI; Walker KJ
    Br J Cancer; 1986 Dec; 54(6):903-9. PubMed ID: 2948537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist.
    Thomas EJ; Jenkins J; Lenton EA; Cooke ID
    Br Med J (Clin Res Ed); 1986 Nov; 293(6559):1407-8. PubMed ID: 2948607
    [No Abstract]   [Full Text] [Related]  

  • 35. Experience with a depot GnRH-agonist (Zoladex) in the treatment of genital endometriosis.
    Mettler L; Steinmüller H; Schachner-Wünschmann E
    Hum Reprod; 1991 May; 6(5):694-8. PubMed ID: 1834693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Therapy with gonadotropin releasing hormone agonists (zoladex) in premenopausal females with metastastic breast cancer].
    Kaufmann M; Schmid H; Kiesel L; Klinga K
    Geburtshilfe Frauenheilkd; 1988 Jul; 48(7):528-32. PubMed ID: 2975241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Goserelin in premenopausal advanced breast cancer: clinical and endocrine evaluation of responsive patients.
    Bajetta E; Zilembo N; Buzzoni R; Celio L; Zampino MG; Colleoni M; Oriana S; Attili A; Sacchini V; Martinetti A
    Oncology; 1994; 51(3):262-9. PubMed ID: 8196909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoladex: therapeutic effects in postmenopausal breast cancer.
    Harris AL; Carmichael J; Cantwell BM; Dowsett M
    Horm Res; 1989; 32 Suppl 1():213-6; discussion 217. PubMed ID: 2533153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of breast cancer with gonadotropin-releasing hormone.
    Manni A; Santen R; Harvey H; Lipton A; Max D
    Endocr Rev; 1986 Feb; 7(1):89-94. PubMed ID: 3082618
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LH-RH agonist, Zoladex (Goserelin), depot formulation in the treatment of prostatic cancer. Randomized dose-finding trial in Japan.
    Kotake T; Usami M; Sonoda T; Matsuda M; Okajima E; Osafune M; Isurugi K; Akaza H; Saitoh Y
    Am J Clin Oncol; 1988; 11 Suppl 2():S108-11. PubMed ID: 2977262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.